Compliance updated on Sep 10, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Allergy Therapeutics PLC

AGY.L ✓ COMPLIANT ☆ Track — members

LSE · Healthcare · Pharmaceuticals ·

UK Small Cap Analyst: STRONG BUY

Last Close

$0.06

▲ +0.00%

Market Cap $406.62M · Vol 359.61K

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$406.62M

Small Cap

Div Yield

N/A

Semi-annual dividend

EPS Growth

-8.20%

YoY

RSI (14)

22.58

Momentum

Beta

1.47

vs Market

52W High

$0.16

61.31% below

52W Low

$0.06

5.56% above

Volume

359.61K

Avg 844.54K

P/B

N/A

Price-to-book

ROE

N/A

Return on equity

Free Float

11.52%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, Allergy Therapeutics PLC (AGY.L) stock is Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does AGY.L pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

-5.00%

-9.52%

-39.87%

-58.70%

YTD

-56.82%

-42.77%

+294.39%

-69.10%

Financials & Valuation

TTM · Annual

Total Revenue	$75.59M
Net Income	$-55,113,504.00
Revenue Growth (YoY)	+6.61%
Gross Margin	45.65%
Operating Margin	-53.60%
Net Profit Margin	-72.91%
ROE	N/A
ROA · ROIC	-58.53% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	6.88
P/B	N/A
P/FCF	N/A
EPS Growth	-8.20%
Outstanding Shares	6.33B

Technical Indicators

50-Day SMA	$0.08
200-Day SMA	$0.12
RSI (14)	22.58
Beta	1.47
52-Week High	$0.16
52-Week Low	$0.06

Volume Today	359.61K
Avg Daily Volume (30D)	844.54K
Relative Volume	0.43x
Volatility (10D)	48.34
Volatility (30D)	55.77
Free Float	11.52%

Analyst Consensus

STRONG BUY

Current Price $0.06

Mean Target $0.17

52W Low$0.06 52W High$0.16

Current

Target

$0.06 $0.16

Current Analyst target

+172.37% upside potential · 1 analysts

Identifiers

ExchangeLSE

FIGIBBG001SGQRM9

ISINGB00B02LCQ05

CountryUK

Sub-IndustryBiopharmaceuticals

Earnings DateDec 9, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

REGN Regeneron Pharmaceuticals, Inc. +1.57% CSL.AX CSL Limited +2.68% 207940.KS SAMSUNG BIOLOGICS CO.,LTD. +0.35% UCB.BR Ucb SA +2.38% BIIB Biogen Inc. +0.10%

Company Profile

Allergy Therapeutics plc is a United Kingdom-based international commercial biotechnology company. The Company is focused on the treatment and diagnosis of allergic disorders, including aluminum free immunotherapies that have the potential to cure disease. It sells proprietary and third-party products from its subsidiaries in nine European countries and via distribution agreements in an additional 10 countries. It sells both injectable and sublingual (oral) allergen-specific immunotherapies. Its pipeline of products in clinical development includes vaccines for grass, tree, house dust mite and peanut. Its therapies are traded under various brand names depending on the market, such as Pollinex Quattro, Polligoid and TA Graser Top. Its commercial products include Pollinex Quattro, Oralvac, Venomil, Venom ATL Polistes Dominula, Synbiotics and Acarovac Plus. Its pipeline candidates include Grass MATA MPL, Birch MATA MPL, Ragweed MATA MPL, Trees MATA MPL, and VLP Peanut.